Daily FNArena News - Small Caps

The full year profit result for Programmed Maintenance Services showed a far stronger second half, leading to increased broker confidence of a recovery year for earnings in FY12.

Thorn Group posted a full year profit at the top end of guidance and with further growth from a broader base expected in coming years brokers continue to see value.

Starpharma should generate first revenues from its VivaGel product this year and Southern Cross sees further upside as the company continues to develop its dendrimer technology.

REVA Medical is developing bioresobable stents for treating coronary artery disease and Southern Cross rates the stock a Spec Buy.

Prima Biomed is moving to late stage clinical trials for its CVac cancer vaccine and Southern Cross sees significant upside potential.

Southern Cross Equities rates Brain Resource a Speculative Buy given potential upside as the company develops offering in the mental health and brain training markets.

Another broker has initiated coverage of clean energy developer Silex Systems, setting a price target for significant upside.

Organic growth and recent acquisitions suggest FY12 will deliver a step change in earnings for BigAir Group, reports Microequities.

DJ Carmichael suggests recent weakness in Ampella’s share price on concerns over civil unrest in Burkina Faso is not justified, so a Buy rating has been reiterated.

Kasbah Resources is developing the Achmmach tin project in Morocco. The project has the potential to grow beyond expectations, says Ord Minnett.